Home
About
Technology
Pipeline
Partners
Investors
News + Resources
- News
- Resource Library
Menu Menu

IJCAHPO 2021 Post Video Form

Clinical Results: MydCombi Efficacy and Safety

Please complete the form below and share any questions you may have for James Tsai, MD

Your Name(Required)

Your Email(Required)

Questions for James Tsai, MD | Clinical Results: MydCombi Efficacy and Safety

Recent Posts

Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference September 7, 2023
Eyenovia Acquires U.S. Commercial Rights To APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) From Formosa Pharmaceuticals August 16, 2023
Eyenovia Announces First Commercial Sale of MydCombi™ August 3, 2023

Pipeline and Technology

MydCombi (Mydriasis)
Apersure (Presbyopia)
MicroPine (Myopia)
Technology

Corporate Address

Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenovia.com

Copyright © 2023 Eyenovia, Inc. All rights reserved.

Twitter
Facebook
LinkedIn

Contact
Safe Harbor
Privacy Policy
Terms of Use